SEC Form 4 · accession 0001209191-18-018515
X4 Pharmaceuticals, Inc · XFOR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Eszter Nagy
Officer — Chief Scientific Officer
Period of report
Mar 7, 2018
Accepted (ET)
Mar 9, 2018 · 4:36 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001501697
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F1 | $17.34 | Mar 7, 2018 | A | 45,000 | A | — | Mar 6, 2028 | Common Stock | 45,000 | 45,000 | D |
Explanation of responses
- F1This option becomes exercisable as to 25% of the shares underlying the award on the first anniversary of the date of grant, with the remainder vesting in equal monthly installments until the fourth anniversary of the date of grant.